EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 235 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR COVID-19: “It could take months to build research up again” July 1, 2020 In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer January 12, 2023 Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High... February 23, 2021 Load more HOT NEWS EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with... Can Age Affect Response to Immune Checkpoint Inhibitors? Using a Mind-Body Connection to Help You Cope During Cancer: An...
